Skip to Main Content

Paper Details

Durability of clinical and immunologic responses to extended low-dose interleukin-2 therapy in patients with refractory chronic graft-versus-host disease.
Front Immunol
1
2022
Author NameAffiliation
Jerome RitzDana-Farber Cancer Institute
Jerome RitzHarvard Medical School
  • 1 - 2

Datasets

Release 1.2